Valuation: NicOx SA

Market Cap 29.61M 34.01M 27.94M 25.39M 47.56M 3.26B 47.75M 334M 129M 1.66B 128M 125M 5.33B P/E 2026 *
-6.72x
P/E 2027 * 16.8x
Enterprise Value 29.61M 34.01M 27.94M 25.39M 47.56M 3.26B 47.75M 334M 129M 1.66B 128M 125M 5.33B EV / Sales 2026 *
9.87x
EV / Sales 2027 * 2.96x
Free-Float
99.65%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 2024-02-27
Director of Finance/CFO 58 2014-12-31
Corporate Officer/Principal - 2005-12-31
Director TitleAgeSince
Director/Board Member 55 2024-04-07
Chairman 64 2024-07-15
Director/Board Member - 2024-07-15
Change 5-day change 1-year change 3-year change Capi.($)
-7.95%-9.39% - - 33.44M
-0.19%+1.49%+81.01%+36.60% 363B
-1.22%-1.37%+20.62%-21.54% 65.62B
+2.53%+5.09%+48.33%+186.72% 12.45B
-0.29%+2.27%-5.37%-16.54% 7.6B
-1.89%-6.83%-27.65%-14.90% 4.49B
-2.06%-3.80%-34.68%+5.56% 4.19B
+1.48%+2.36%-31.20%-13.91% 2.92B
-2.14%+0.74%-6.25%+43.69% 2.49B
-0.41%-0.71%-28.25%-33.78% 1.93B
Average -1.22%+0.50%+1.84%+19.10% 51.64B
Weighted average by Cap. -0.36%+1.38%+66.47%+30.19%

Financials

2026 *2027 *
Net sales 3M 3.45M 2.83M 2.57M 4.82M 330M 4.84M 33.86M 13.08M 168M 12.94M 12.65M 540M 10M 11.49M 9.44M 8.57M 16.06M 1.1B 16.13M 113M 43.61M 560M 43.13M 42.17M 1.8B
Net income -5M -5.74M -4.72M -4.29M -8.03M -551M -8.06M -56.43M -21.8M -280M -21.57M -21.09M -901M 2M 2.3M 1.89M 1.71M 3.21M 220M 3.23M 22.57M 8.72M 112M 8.63M 8.43M 360M
Net Debt - -
Logo NicOx SA
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!